Cascadian Therapeutics (FRA:3O61) Total Liabilities : €9.96 Mil (As of Dec. 2017)

View and export this data going back to . Start your Free Trial

What is Cascadian Therapeutics Total Liabilities?

Cascadian Therapeutics's Total Liabilities for the quarter that ended in Dec. 2017 was €9.96 Mil.

Cascadian Therapeutics's quarterly Total Liabilities increased from Jun. 2017 (€6.77 Mil) to Sep. 2017 (€7.36 Mil) and increased from Sep. 2017 (€7.36 Mil) to Dec. 2017 (€9.96 Mil).

Cascadian Therapeutics's annual Total Liabilities declined from Dec. 2015 (€11.79 Mil) to Dec. 2016 (€8.45 Mil) but then increased from Dec. 2016 (€8.45 Mil) to Dec. 2017 (€9.96 Mil).

Cascadian Therapeutics Total Liabilities Historical Data

The historical data trend for Cascadian Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cascadian Therapeutics Total Liabilities Chart

Cascadian Therapeutics Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Total Liabilities

Get a 7-Day Free Trial

4.52

9.60

11.79

8.45

9.96

Cascadian Therapeutics Quarterly Data
	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17
Total Liabilities	Get a 7-Day Free Trial															8.45	5.13	6.77	7.36	9.96

Cascadian Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cascadian Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2017 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	9.936	+	(0	+	0.025999999999989
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	9.96

Total Liabilities	=	Total Assets (A: Dec. 2017 )	-	Total Equity (A: Dec. 2017 )
	=	102.097	-	92.135
	=	9.96

Cascadian Therapeutics's Total Liabilities for the quarter that ended in Dec. 2017 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	9.936	+	(0	+	0.025999999999989
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	9.96

Total Liabilities	=	Total Assets (Q: Dec. 2017 )	-	Total Equity (Q: Dec. 2017 )
	=	102.097	-	92.135
	=	9.96

Cascadian Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Cascadian Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cascadian Therapeutics (FRA:3O61) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cascadian Therapeutics Inc (FRA:3O61) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cascadianrx.com

Cascadian Therapeutics Inc is a clinical-stage biopharmaceutical company focusing in developing innovative therapeutic product candidates for the treatment of cancer. Its objective is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. The company's clinical-stage product candidate includes ONT-380, an orally active and selective small molecule HER2 inhibitor. In addition, it is also engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 kinase inhibitor and protocell technology. All the business activity of the firm is functioned through the region of United States.

Cascadian Therapeutics (FRA:3O61) Headlines

No Headlines